GlassScriptPhysician profile
Michael G Gaines
NPI 1497778047
$2,065.68
in general payments reported to CMS, 2019-2025
25 companies · $39.41 in 2025
The $39.41 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $275 · 2020: $283 · 2021: $380 · 2022: $335 · 2023: $607 · 2024: $146 · 2025: $39.41.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $793.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $792.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $399.53 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $349.31 | 2019-2024 | Stiolto Respimat |
| Pfizer INC. | $236.09 | 2019-2022 | |
| Glaxosmithkline, LLC. | $169.94 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $137.91 | 2020-2024 | Mounjaro, Jardiance |
| Novo Nordisk INC | $76.79 | 2020-2024 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $72.75 | 2022-2023 | Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $71.56 | 2022-2023 | |
| Terumo Medical Corporation | $69.45 | 2019 | |
| Exact Sciences Corporation | $59.07 | 2023-2025 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $50.69 | 2022-2023 | Rexulti |
| Eisai INC. | $48.40 | 2020-2021 | |
| Phathom Pharmaceuticals, INC. | $44.19 | 2024 | Voquezna |
| Genentech USA, INC. | $42.28 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $40.89 | 2023 | Xifaxan |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $40.25 | 2022 | |
| Redhill Biopharma INC. | $23.34 | 2020 | |
| Abbott Laboratories | $23.00 | 2021 | |
| Allergan, INC. | $22.74 | 2020 | |
| Melinta Therapeutics, LLC | $19.22 | 2019 | |
| Shield Therapeutics INC | $16.41 | 2023 | Accrufer |
| Currax Pharmaceuticals LLC | $15.14 | 2023 | Contrave |
| Teva Pharmaceuticals USA, INC. | $13.43 | 2019 | |
| G Medical Diagnostic Services, INC. | $12.26 | 2020 | |
| Merck Sharp & Dohme LLC | $11.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Gaines listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.